Veligrotug, sold under the brand name Lumvoa, is a monoclonal antibody medication used for the treatment of thyroid eye disease. It is an insulin-like growth factor-1 receptor inhibitor. It is given via intravenous injection.
Veligrotug was approved for medical use in the United States in June 2026.
Medical uses Veligrotug is indicated for the treatment of thyroid eye disease regardless of thyroid eye disease activity or duration.
Society and culture Legal status Veligrotug was approved for medical use in the United States in June 2026.
Names Veligrotug is the international nonproprietary name.
Veligrotug is sold under the brand name Lumvoa.
References
External links